Aliases & Classifications for Ureteral Obstruction

MalaCards integrated aliases for Ureteral Obstruction:

Name: Ureteral Obstruction 12 54 43 15

External Ids:

Disease Ontology 12 DOID:5199
ICD9CM 34 593.4
MeSH 43 D014517
UMLS 71 C0029866

Summaries for Ureteral Obstruction

MalaCards based summary : Ureteral Obstruction is related to hydronephrosis and renal fibrosis. An important gene associated with Ureteral Obstruction is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are TGF-Beta Pathway and p70S6K Signaling. The drugs Silodosin and Opium have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and bone, and related phenotypes are cardiovascular system and growth/size/body region

Related Diseases for Ureteral Obstruction

Diseases related to Ureteral Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 333)
# Related Disease Score Top Affiliating Genes
1 hydronephrosis 32.0 TGFB1 SLC12A1 AQP2 AGTR2
2 renal fibrosis 31.9 TGFB1 NFE2L2 ENG BMP7 AGTR1
3 urinary tract obstruction 31.7 TGFB1 PTGS2 BMP7 AQP2 AGTR1
4 vesicoureteral reflux 1 31.3 TGFB1 AGTR2 AGTR1
5 chronic kidney disease 31.2 TGFB1 IL10 EPO BMP7 AQP2 AGTR1
6 end stage renal failure 31.1 TGFB1 PTGS2 EPO AGTR2 AGTR1
7 glomerulonephritis 30.9 TGFB1 NOS2 LRP2 AGTR1
8 kidney disease 30.9 TGFB1 SLC12A1 NOS2 EPO BMP7 AQP2
9 nephrolithiasis, calcium oxalate 30.8 SLC9A3 SLC12A1 LRP2 AQP2
10 posterior urethral valves 30.8 TGFB1 AGTR2 AGTR1
11 proteasome-associated autoinflammatory syndrome 1 30.4 PTGS2 NOS2 IL10
12 nephrosclerosis 30.4 TGFB1 BMP7 AGTR1
13 schistosomiasis 30.4 TP53 TGFB1 IL10
14 ureteral disease 30.4 TGFB1 BMP7 AQP2 AGTR1
15 prostatitis 30.3 TP53 TGFB1 IL10
16 adenomyosis 30.2 TP53 PTGS2 CTNNB1
17 pre-eclampsia 30.2 NOS2 IL10 ENG AGTR2 AGTR1
18 acquired immunodeficiency syndrome 30.1 TP53 NOS2 IL10 EPO
19 colitis 30.0 PTGS2 NOS2 IL10 CTNNB1
20 inflammatory bowel disease 29.4 TP53 TGFB1 SLC9A3 PTGS2 NOS2 IL10
21 vascular disease 29.3 TP53 TGFB1 PTGS2 PDGFA NOX4 NOS2
22 hypertension, essential 28.6 TP53 TGFB1 SLC9A3 SLC12A1 PTGS2 NOX4
23 obstructive nephropathy 10.8
24 fibrosis of extraocular muscles, congenital, 1 10.8
25 endometriosis 10.7
26 acute kidney failure 10.7
27 retroperitoneal fibrosis 10.7
28 aneurysm 10.6
29 juvenile myasthenia gravis 10.6 TGFB1 IL10
30 anuria 10.6
31 pyelonephritis 10.5
32 aortic aneurysm 10.5
33 leukoregulin 10.5 TGFB1 PTGS2
34 spotted fever rickettsiosis 10.5 NOS2 IL10
35 familial vesicoureteral reflux 10.5 TGFB1 AGTR2
36 acute cystitis 10.5
37 trachoma 10.5 TGFB1 IL10 ENG
38 vulvar intraepithelial neoplasia 10.5 TP53 CTNNB1
39 peyronie disease 10.5 TGFB1 NOS2
40 renal tubular transport disease 10.5 SLC12A1 LRP2 AQP2
41 bone squamous cell carcinoma 10.4 TP53 ENG CTNNB1
42 aortic aneurysm, familial abdominal, 1 10.4
43 adult teratoma 10.4 TP53 ENG
44 dent disease 1 10.4 SLC9A3 SLC12A1 LRP2
45 cystitis 10.4
46 renal hypertension 10.4 EPO AGTR2 AGTR1
47 osteonecrosis 10.4 IL10 ENG BMP7
48 leptospirosis 10.4 SLC9A3 SLC12A1 IL10
49 uremia 10.4
50 pneumoconiosis 10.4 TGFB1 PTGS2 IL10

Graphical network of the top 20 diseases related to Ureteral Obstruction:

Diseases related to Ureteral Obstruction

Symptoms & Phenotypes for Ureteral Obstruction

MGI Mouse Phenotypes related to Ureteral Obstruction:

45 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.55 AGTR1 AGTR2 BMP7 CTNNB1 ENG EPO
2 growth/size/body region MP:0005378 10.5 ADAMTS1 AGTR1 AGTR2 AQP2 BMP7 CTNNB1
3 homeostasis/metabolism MP:0005376 10.5 ADAMTS1 AGTR1 AGTR2 AQP2 CTNNB1 ENG
4 behavior/neurological MP:0005386 10.45 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 ENG
5 hematopoietic system MP:0005397 10.44 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 ENG
6 digestive/alimentary MP:0005381 10.42 AGTR2 BMP7 CTNNB1 ENG IL10 LRP2
7 mortality/aging MP:0010768 10.41 ADAMTS1 AGTR1 AGTR2 AQP2 BMP7 CTNNB1
8 immune system MP:0005387 10.36 AGTR1 AGTR2 BMP7 CTNNB1 EPO IL10
9 integument MP:0010771 10.34 AGTR2 AQP2 BMP7 CTNNB1 ENG EPO
10 cellular MP:0005384 10.33 AGTR2 CTNNB1 EPO IL10 LRP2 NFE2L2
11 embryo MP:0005380 10.31 BMP7 CTNNB1 ENG EPO IL10 LRP2
12 endocrine/exocrine gland MP:0005379 10.3 ADAMTS1 AGTR2 BMP7 CTNNB1 IL10 LRP2
13 craniofacial MP:0005382 10.28 BMP7 CTNNB1 ENG IL10 LRP2 NFE2L2
14 adipose tissue MP:0005375 10.26 ADAMTS1 AGTR1 AGTR2 NFE2L2 NOS2 PTGS2
15 renal/urinary system MP:0005367 10.19 ADAMTS1 AGTR1 AGTR2 AQP2 BMP7 CTNNB1
16 nervous system MP:0003631 10.17 AGTR1 AGTR2 BMP7 CTNNB1 ENG IL10
17 muscle MP:0005369 10.14 AGTR2 CTNNB1 ENG EPO IL10 NOS2
18 liver/biliary system MP:0005370 10.06 CTNNB1 EPO IL10 NFE2L2 NOS2 PTGS2
19 limbs/digits/tail MP:0005371 10.02 BMP7 CTNNB1 EPO IL10 LRP2 SFRP4
20 reproductive system MP:0005389 10 ADAMTS1 AQP2 BMP7 CTNNB1 IL10 LRP2
21 neoplasm MP:0002006 9.97 AGTR2 CTNNB1 IL10 NFE2L2 NOS2 PTGS2
22 respiratory system MP:0005388 9.8 BMP7 CTNNB1 ENG EPO IL10 LRP2
23 skeleton MP:0005390 9.47 AGTR2 BMP7 CTNNB1 EPO IL10 LRP2

Drugs & Therapeutics for Ureteral Obstruction

Drugs for Ureteral Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 93)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Silodosin Approved Phase 4 160970-54-7
Opium Approved, Illicit Phase 4 8008-60-4
Scopolamine Approved, Investigational Phase 4 51-34-3, 6533-68-2 5184
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Belladonna Approved, Experimental Phase 4
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
Loperamide Approved Phase 4 53179-11-6 3955
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
BCG vaccine Investigational Phase 4
11 Tolterodine tartrate Phase 4 124937-52-6
12 Analgesics Phase 4
13 Gastrointestinal Agents Phase 4
14 Narcotics Phase 4
15 Opium Poppy Phase 4
16 Analgesics, Opioid Phase 4
17 Antitussive Agents Phase 4
18 Respiratory System Agents Phase 4
19 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
20 Central Nervous System Depressants Phase 4
21 Butylscopolammonium Bromide Phase 4
22 Antidiarrheals Phase 4
23 Neurotransmitter Agents Phase 4
24 Adrenergic alpha-Antagonists Phase 4
25 Adrenergic Antagonists Phase 4
26 Adrenergic Agents Phase 4
27 Immunologic Factors Phase 4
28 Anti-Bacterial Agents Phase 4
29 Alkylating Agents Phase 4
30 Vaccines Phase 4
31 Antibiotics, Antitubercular Phase 4
32 Mitomycins Phase 4
33 Adjuvants, Immunologic Phase 4
34 Hemostatics Phase 3
35 Fibrin Tissue Adhesive Phase 3
36 Coagulants Phase 3
Tamoxifen Approved Phase 2 10540-29-1 2733526
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
Iodine Approved, Investigational Phase 2 7553-56-2 807
Triclosan Approved, Investigational Phase 2 3380-34-5 5564
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
Mirabegron Approved Phase 2 223673-61-8 9865528
Gemcitabine Approved Phase 2 95058-81-4 60750
44 Anti-Inflammatory Agents Phase 2
45 Estrogens Phase 2
46 Selective Estrogen Receptor Modulators Phase 2
47 Estrogen Antagonists Phase 2
48 Antineoplastic Agents, Hormonal Phase 2
49 Estrogen Receptor Antagonists Phase 2
50 glucocorticoids Phase 2

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA™) in Ureteral Obstruction: Prospective, Multi-center, Open Label Study Unknown status NCT01788865 Phase 4
2 Effect of a Silicone Hydrocoated Double Loop Ureteral Stent on Symptoms and Quality of Life in Patients Undergoing F-URS for Kidney Stone; a Comparative Randomized Multicenter Clinical Study. Unknown status NCT02489656 Phase 4
3 Combination Versus Monotherapy With Alpha Blocker and Anticholinergics to Relieve Urinary Stent Symptoms Completed NCT01741454 Phase 4 Tamsulosin;Tolterodine ER
4 A 4-week, Double-blind, Randomized, Comparative and Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones. Completed NCT01533389 Phase 4 Silodosin;Placebo
5 Interest of MR Urography in the Evaluation of Functional Consequences of Urinary Tract in Children and Adults Completed NCT00301470 Phase 4
6 The Use of Belladonna and Opium (B&O) Suppository in the Treatment of Postoperative Stent Pain: A Randomized, Double-Blinded Control Study Completed NCT03332056 Phase 4 Belladonna and Opium
7 The Effect of Daily Versus Twice Per Day Tamsulosin on Ureteral Stent Symptoms Following Ureteroscopy for Nephrolithiasis Enrolling by invitation NCT03799120 Phase 4 Tamsulosin BID
8 The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer Not yet recruiting NCT03790384 Phase 4 Mitomycin
9 Application of the Biological Fibrin Based Adhesive for the Prevention of Surgical Complications in the Kidney Transplant Completed NCT01631448 Phase 3
10 Comparison of the Efficacy of Silicone-covered Metallic Ureteral Stent and Double-J Stent for Malignant Ureteral Obstruction: A Prospective Randomized Controlled Trial Based on Exploratory Research Unknown status NCT01823575 Phase 2
11 A Randomised Trial of Prednisone and Tamoxifen in Patients With Idiopathic Retroperitoneal Fibrosis Unknown status NCT00440349 Phase 2 Tamoxifen;Prednisone
12 Study of Tolerance and Effectiveness of Ureteral Stents MEMOKATH ® 051 in the Treatment of Chronic Strictures of the Ureter Completed NCT00790686 Phase 2
13 Assessment of Bacterial Adherence and Biofilm Formation on a Triclosan Loaded Ureteral Stent: A Phase II Study Completed NCT00250406 Phase 2
14 A Randomized Control Trial Comparing Single to Multiple Application Lidocaine Analgesia Prior to Urethral Catheterization Procedures Completed NCT00142064 Phase 2
15 A Double Blind Placebo Control Trial of Mirabegron for Medical Expulsive Therapy and to Manage Stent Pain for Ureteral Stones(Protocol # 01-16-20-02) Recruiting NCT02744430 Phase 2 Mirabegron
16 A Phase II Clinical Trial to Evaluate the Potential of Concomitant Chemoradiotherapy With Gemcitabine in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease Recruiting NCT03101995 Phase 2 Gemcitabine
17 Ureteral Reimplantation for the Treatment of Extrinsic Malignant Ureteral Obstruction Unknown status NCT02160652
18 Ureteropelvic Junction Obstruction in Early Childhood: Comparison of Surgical Therapy and Surveillance in Children With Scintigraphically Prooved Obstruction. A Prospective, Randomized, Controlled Multi-Center Study Unknown status NCT00444431
19 The Correlation Between Renal Injury and Biomarkers in Pediatric Ureteropelvic Junction Obstruction Patients Unknown status NCT01711996
20 Potentially Nephroprotective Effects of Carnitine and Phosphodiesterase Type 5 (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN): A Double Blind Randomized Study Unknown status NCT01564303 Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine
21 Urinary Biomarkers as Predictors on Renal Function in Congenital Hydronephrosis Completed NCT00568724
22 Laparoscopic Pyeloplasty: A Registry and Database Completed NCT00169650
23 Long-Term Temporary Drainage of Malignant Extrinsic Ureteral Obstruction Secondary to Inoperable Pelvic or Abdominal Malignancies Using the Memokath 051 Ureteral Stent Completed NCT00166361
24 Evaluation of Ureteral Length Measurement by Computed Tomography (CT) to Actual Ureteral Length Measured by Ureteral Catheterization Completed NCT01542593
25 Lower UTI Evaluation in Women With Uterine Leiomyomata Completed NCT01123603
26 The Efficacy and Safety of Local Anesthetic Infusion With Ropivacaine for the Management of Pain After Surgical Correction of Ureteropelvic Junction Stenosis Completed NCT00930046
27 Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms: A Randomized Controlled Trial Recruiting NCT03709992 Trospium Chloride;Tamsulosin
28 Double-blind, Placebo-controlled Randomized Controlled Trial of NSAID Prior to Ureteral Stent Removal in a Pediatric Population Recruiting NCT02140970 Ibuprofen;Placebo
29 Prospective Multicenter Observational Study of Early Infancy Ureteral Reimplantation for Distal Ureteral Obstruction Recruiting NCT02419339
30 Cystoprostatectomy Versus Radiotherapy Combined With Androgen Deprivation Therapy for the Treatment of Clinical T4 Prostate Cancer With Bladder Invasion: a Multicentre, Prospective, Open, Randomized Clinical Trial Recruiting NCT03482089
31 Is Routine Urinary Bladder Catheterization Necessary After Ureteroscopy and Double J Stent Placement? Recruiting NCT03713411
32 Multi-Center Comparison of Dual Lumen Versus Single Lumen Ureteroscopes Recruiting NCT02123082
33 Effect of a Low Residue Diet in Comparison to the Dietary Recommendations From the INCan: A Randomized Clinical Trial to Assess Malnutrition, Gastrointestinal Toxicity and Quality of Life of Advanced Cervical Cancer Patients (IB2-IVA) Recruiting NCT03100409
34 Phase-I Feasibility Trial To Study The Safety Of Laser Tissue Welding For Sealing Resected Kidney Surfaces After Laparoscopic Partial Nephrectomy Active, not recruiting NCT02061605
35 Boston Scientific Double-J Ureteral Stent Postmarket Patient Registry Not yet recruiting NCT04197583
36 The RELIEF™ Ureteral Stent - Assessment of Retrograde Urinary Reflux and Distal Coil Bladder Position Not yet recruiting NCT03266770
37 Cortical Transit Time on Diuretic Renogram as an Early Marker of Significant Obstruction in Antenatally Detected Uretero-pelvic Junction Syndrome Not yet recruiting NCT02812212
38 Prospective Randomized Trial of Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty Terminated NCT02713633
39 Comparison of Dynamic Contrast Enhanced CT and Diuretic Renogram in The Evaluation of Ureteropelvic Junction Obstruction Withdrawn NCT00199472

Search NIH Clinical Center for Ureteral Obstruction

Cochrane evidence based reviews: ureteral obstruction

Genetic Tests for Ureteral Obstruction

Anatomical Context for Ureteral Obstruction

MalaCards organs/tissues related to Ureteral Obstruction:

Kidney, Prostate, Bone, Colon, Cervix, Endothelial, Monocytes

Publications for Ureteral Obstruction

Articles related to Ureteral Obstruction:

(show top 50) (show all 4824)
# Title Authors PMID Year
IL-18 neutralization ameliorates obstruction-induced epithelial-mesenchymal transition and renal fibrosis. 54 61
19536084 2009
Angiotensin II type 1 receptor blockade prevents decrease in adult stem-like cells in kidney after ureteral obstruction. 54 61
17692840 2007
Snail1 is involved in the renal epithelial-mesenchymal transition. 54 61
17692821 2007
Cyclooxygenase type 2 is increased in obstructed rat and human ureter and contributes to pelvic pressure increase after obstruction. 54 61
16820795 2006
Elevated plasma concentrations of transforming growth factor-beta 1 in patients with unilateral ureteral obstruction. 54 61
16315065 2005
Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. 54 61
15153562 2004
Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. 54 61
10894795 2000
A review on urinary proteins in outflow disease of the upper urinary tract. 54 61
10841920 2000
Increased expression of TGF-beta1 but not of its receptors contributes to human obstructive nephropathy. 54 61
10594789 1999
Effects of experimental ureteral obstruction on platelet-derived growth factor-A and type I procollagen expression in fetal metanephric kidneys. 54 61
7819000 1994
SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. 54 61
1895664 1991
WNT1-inducible signaling protein-1 mediates TGF-β1-induced renal fibrosis in tubular epithelial cells and unilateral ureteral obstruction mouse models via autophagy. 61
31512238 2020
O-GlcNAcylation of RAF1 increases its stabilization and induces the renal fibrosis. 61
31521821 2020
Effects of Rikkunshito treatment on renal fibrosis/inflammation and body weight reduction in a unilateral ureteral obstruction model in mice. 61
32024850 2020
Protein arginine methyltransferase 1 mediates renal fibroblast activation and fibrogenesis through activation of Smad3 signaling. 61
31813251 2020
H2S alleviates renal injury and fibrosis in response to unilateral ureteral obstruction by regulating macrophage infiltration via inhibition of NLRP3 signaling. 61
31846625 2020
High-volume Concurrent Polypoid Ureteritis and Ureteritis Cystica Manifesting With Ureteral Obstruction. 61
31866522 2020
Outcome of Palliative Urinary Diversion and Observation for Malignant Extrinsic Ureteral Obstruction. 61
31834827 2020
The effect of oleuropein on unilateral ureteral obstruction induced-kidney injury in rats: the role of oxidative stress, inflammation and apoptosis. 61
31873871 2020
Complications After Reperitonealization of Mesh at Time of Sacrocolpopexy: A Retrospective Cohort Study. 61
31990799 2020
Application of metallic ureteral stents in gynecological malignancies: a literature review. 61
30793634 2020
Loss of Histone H3 K79 Methyltransferase Dot1l Facilitates Kidney Fibrosis by Upregulating Endothelin 1 through Histone Deacetylase 2. 61
31843983 2020
Two-step treatment model for the adult patients with an obstructed kidney functioning below 10% of its capacity: a pilot study. 61
31655937 2020
RIG-I aggravates interstitial fibrosis via c-Myc-mediated fibroblast activation in UUO mice. 61
32036390 2020
Effects of Heterozygous TfR1 (Transferrin Receptor 1) Deletion in Pathogenesis of Renal Fibrosis in Mice. 61
31838906 2020
HUWE1 promotes EGFR ubiquitination and degradation to protect against renal tubulointerstitial fibrosis. 61
32017279 2020
Deletion of FHL2 in fibroblasts attenuates fibroblasts activation and kidney fibrosis via restraining TGF-β1-induced Wnt/β-catenin signaling. 61
31927599 2020
Inhibition of lysyl oxidase ameliorates renal injury by inhibiting CD44-mediated pericyte detachment and loss of peritubular capillaries. 61
31927047 2020
Sirtuin 3 Activation by Honokiol Decreases Unilateral Ureteral Obstruction-Induced Renal Inflammation and Fibrosis via Regulation of Mitochondrial Dynamics and the Renal NF-κBTGF-β1/Smad Signaling Pathway. 61
31936371 2020
Targeted delivery of celastrol to renal interstitial myofibroblasts using fibronectin-binding liposomes attenuates renal fibrosis and reduces systemic toxicity. 61
31931051 2020
Cystatin C in Evaluating Renal Function in Ureteral Calculi Hydronephrosis in Adults. 61
31801142 2020
Erythropoietin promotes functional recovery via anti-apoptotic mechanisms in mouse unilateral ureteral obstruction. 61
31970695 2020
Kidney injury enhances renal G-CSF expression and modulates granulopoiesis and human neutrophil CD177 in vivo. 61
31509227 2020
Improved Long Ureteral Reconstruction With Ileum By Longitudinal Clipping And Mucosal Stripping: An Animal Study. 61
31912471 2020
Spontaneous distal ureteric rupture: A rare case report and review of literature. 61
31970074 2020
Diagnostic imaging observations in cats treated with the subcutaneous ureteral bypass system. 61
31592537 2020
An unusual complication of urinary stone disease: Spontaneous ureteral rupture. 61
31924441 2020
The Impact of Ureteral Deformation and External Ureteral Pressure on Stent Failure in Extrinsic Ureteral Obstruction: An In Vitro Experimental Study. 61
31359787 2020
Letter to the Editor RE: Schwartz, Editorial Comment on: The Impact of Ureteral Deformation and External Ureteral Pressure on Stent Failure in Extrinsic Ureteral Obstruction--An In Vitro Experimental Study by Shilo et al. (From: Shilo Y, Modai J, Leibovici D, et al. J Endourol 2019;34:74; DOI: 10.1089/end.2019.0636). 61
31895594 2020
Editorial Comment on: The Impact of Ureteral Deformation and External Ureteral Pressure on Stent Failure in Extrinsic Ureteral Obstruction: An In Vitro Experimental Study by Shilo et al. (From: Shilo Y, Modai J, Leibovici D, et al. J Endourol 2019;34:68-73; DOI: 10.1089/end.2019.0465). 61
31583897 2020
Bilateral ureteral obstruction is rapidly accompanied by ER stress and activation of autophagic degradation of IMCD proteins, including AQP2. 61
31736351 2020
Ameliorating effect of troxerutin in unilateral ureteral obstruction induced renal oxidative stress, inflammation, and apoptosis in male rats. 61
31900517 2020
Compound K inhibits priming and mitochondria-associated activating signals of NLRP3 inflammasome in renal tubulointerstitial lesions. 61
31065699 2020
The long noncoding RNA myocardial infarction-associated transcript modulates the epithelial-mesenchymal transition in renal interstitial fibrosis. 61
31863776 2020
Evaluation of dynamic thiol-disulphide homeostasis in obstructive uropathy. 61
31955364 2020
Treatment of ureteral catheter related symptoms; mirabegron versus tamsulosin/solifenacin combination: A randomized controlled trial. 61
31950924 2020
Proximal Tubule Translational Profiling during Kidney Fibrosis Reveals Proinflammatory and Long Noncoding RNA Expression Patterns with Sexual Dimorphism. 61
31537650 2020
Prediction of the mechanisms of action of Shenkang in chronic kidney disease: A network pharmacology study and experimental validation. 61
31386888 2020
Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy. 61
31810653 2020
Efficiency and Safety of the Sting Operation on Kidney Transplanted Patients with Symptomatic Vesicoureteral Reflux and Neurogenic Bladder Dysfunction. 61
31901322 2020

Variations for Ureteral Obstruction

Expression for Ureteral Obstruction

Search GEO for disease gene expression data for Ureteral Obstruction.

Pathways for Ureteral Obstruction

Pathways related to Ureteral Obstruction according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.17 TGFB1 PTGS2 NOS2 IL10
Show member pathways
12.16 TP53 TGFB1 PDGFA IL10 BMP7
8 12.02 TP53 TGFB1 PTGS2 NOS2 CTNNB1
10 11.98 TP53 PDGFA NFE2L2 CTNNB1
11 11.8 TP53 TGFB1 PTGS2 NOX4 NOS2
12 11.77 TP53 PTGS2 NOS2
14 11.71 TP53 TGFB1 PTGS2 NOS2 IL10
Show member pathways
16 11.6 TP53 TGFB1 CTNNB1 BMP7
17 11.59 NOS2 EPO ENG
18 11.59 TGFB1 BMP7 ADAMTS1
19 11.53 TGFB1 PDGFA NFE2L2 BMP7
20 11.52 TGFB1 ENG CTNNB1
21 11.42 TGFB1 PDGFA EPO
22 11.38 TP53 TGFB1 PTGS2 NOS2
23 11.24 TP53 PTGS2 NOS2
25 11.13 TGFB1 PDGFA IL10
26 11.02 TP53 PTGS2 NOS2 EPO

GO Terms for Ureteral Obstruction

Cellular components related to Ureteral Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.63 TGFB1 SLC9A3 SFRP4 PDGFA EPO ENG
2 apical plasma membrane GO:0016324 9.35 SLC9A3 SLC12A1 NOX4 LRP2 AQP2
3 cell GO:0005623 9.28 TP53 SLC9A3 SLC12A1 NOX4 NOS2 NFE2L2

Biological processes related to Ureteral Obstruction according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.22 TP53 TGFB1 NFE2L2 IL10 ENG CTNNB1
2 negative regulation of apoptotic process GO:0043066 10.08 TP53 PTGS2 LRP2 IL10 EPO CTNNB1
3 positive regulation of cell proliferation GO:0008284 10.07 TGFB1 PTGS2 PDGFA EPO CTNNB1 AGTR2
4 positive regulation of transcription, DNA-templated GO:0045893 10.01 TP53 TGFB1 NFE2L2 IL10 EPO CTNNB1
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.99 TGFB1 PDGFA NOX4 EPO
6 cytokine-mediated signaling pathway GO:0019221 9.98 TP53 TGFB1 PTGS2 NOS2 IL10
7 positive regulation of gene expression GO:0010628 9.98 TP53 TGFB1 SFRP4 NFE2L2 ENG CTNNB1
8 regulation of apoptotic process GO:0042981 9.97 TP53 TGFB1 CTNNB1 BMP7 AGTR2
9 negative regulation of gene expression GO:0010629 9.97 TP53 TGFB1 NOS2 ENG CTNNB1
10 response to lipopolysaccharide GO:0032496 9.96 PTGS2 NOS2 IL10 EPO
11 response to hypoxia GO:0001666 9.95 TGFB1 NOX4 NOS2 EPO
12 response to drug GO:0042493 9.93 TP53 TGFB1 PTGS2 IL10 ENG CTNNB1
13 heart development GO:0007507 9.92 TP53 TGFB1 LRP2 ENG CTNNB1
14 cellular response to hypoxia GO:0071456 9.91 TP53 PTGS2 NFE2L2 BMP7
15 cell proliferation GO:0008283 9.91 TP53 TGFB1 LRP2 EPO CTNNB1
16 inflammatory response GO:0006954 9.91 TGFB1 PTGS2 NOX4 NFE2L2 IL10 AGTR2
17 response to organic substance GO:0010033 9.89 TGFB1 PTGS2 IL10
18 BMP signaling pathway GO:0030509 9.89 TGFB1 ENG BMP7
19 cellular response to mechanical stimulus GO:0071260 9.88 TGFB1 PTGS2 ENG
20 positive regulation of protein kinase B signaling GO:0051897 9.88 TGFB1 PDGFA NOX4 LRP2 ENG
21 positive regulation of apoptotic process GO:0043065 9.87 TP53 TGFB1 SFRP4 PTGS2 NOX4 CTNNB1
22 cellular response to growth factor stimulus GO:0071363 9.86 TGFB1 LRP2 CTNNB1
23 cellular response to drug GO:0035690 9.86 TP53 NOS2 NFE2L2
24 positive regulation of MAP kinase activity GO:0043406 9.85 TGFB1 PDGFA NOX4
25 vasculogenesis GO:0001570 9.85 TGFB1 ENG CTNNB1
26 kidney development GO:0001822 9.85 CTNNB1 BMP7 AGTR1 ADAMTS1
27 response to estradiol GO:0032355 9.84 TGFB1 PTGS2 CTNNB1 BMP7
28 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.82 TGFB1 ENG BMP7
29 negative regulation of cell cycle GO:0045786 9.81 TGFB1 PTGS2 BMP7
30 positive regulation of epithelial to mesenchymal transition GO:0010718 9.81 TGFB1 CTNNB1 BMP7
31 epithelial to mesenchymal transition GO:0001837 9.79 TGFB1 CTNNB1 BMP7
32 negative regulation of mitotic cell cycle GO:0045930 9.79 TP53 TGFB1 IL10
33 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.73 TP53 TGFB1 IL10
34 regulation of cell proliferation GO:0042127 9.73 TP53 TGFB1 PTGS2 NOS2 CTNNB1 AGTR1
35 cellular response to fluid shear stress GO:0071498 9.71 PTGS2 NFE2L2
36 positive regulation of histone deacetylation GO:0031065 9.71 TP53 TGFB1
37 cell activation GO:0001775 9.71 TGFB1 PDGFA
38 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.7 TP53 TGFB1
39 response to salt stress GO:0009651 9.7 TP53 EPO
40 salivary gland morphogenesis GO:0007435 9.7 TGFB1 BMP7
41 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.7 TP53 TGFB1
42 regulation of protein import into nucleus GO:0042306 9.69 TGFB1 AGTR2
43 angiotensin-activated signaling pathway GO:0038166 9.69 AGTR2 AGTR1
44 regulation of removal of superoxide radicals GO:2000121 9.67 NFE2L2 BMP7
45 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.67 TP53 NFE2L2
46 response to vitamin D GO:0033280 9.67 TGFB1 PTGS2 BMP7
47 negative regulation of neuroblast proliferation GO:0007406 9.66 TP53 TGFB1
48 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.66 TP53 NFE2L2
49 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress GO:1902219 9.64 PTGS2 EPO
50 central nervous system vasculogenesis GO:0022009 9.63 ENG CTNNB1

Molecular functions related to Ureteral Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 TP53 TGFB1 SLC9A3 SFRP4 PTGS2 PDGFA
2 protein homodimerization activity GO:0042803 9.93 TP53 TGFB1 PTGS2 PDGFA NOS2 ENG
3 cytokine activity GO:0005125 9.71 TGFB1 IL10 EPO BMP7
4 type I transforming growth factor beta receptor binding GO:0034713 9.43 TGFB1 ENG
5 RNA polymerase II activating transcription factor binding GO:0001102 9.43 TP53 NFE2L2 CTNNB1
6 type II transforming growth factor beta receptor binding GO:0005114 9.37 TGFB1 ENG
7 transcription cofactor binding GO:0001221 9.32 TP53 NFE2L2
8 growth factor activity GO:0008083 9.26 TGFB1 PDGFA IL10 BMP7
9 angiotensin type II receptor activity GO:0004945 8.62 AGTR2 AGTR1

Sources for Ureteral Obstruction

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....